Top Markets
Coin of the day
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
Rang in aandelen #33998
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
Aandeelprijs
$0.1502
Laatst gesynchroniseerd: 2024-11-04
Marktkapitalisatie
$6.43M
Verandering (1 dag)
-5.45%
Verandering (1 jaar)
0.00%
Land
US
Handel Renalytix Plc (RNLX)

Categorie

Winst voor Renalytix Plc (RNLX)
Winst in Sep 2024 TTM: $-28.67M
Volgens de meest recente financiële verslagen van Renalytix Plc bedraagt de huidige winst van het bedrijf $-28.67M. In 2023 behaalde het bedrijf een winst van $-46.22M, een daling ten opzichte van de winst van 2022, die $-45.25M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Renalytix Plc van 2018 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $-28.67M -14.29%
2024 $-33.45M -27.63%
2023 $-46.22M 2.14%
2022 $-45.25M 26.44%
2021 $-35.79M 237.30%
2020 $-10.61M 62.78%
2019 $-6.52M 1,459.33%
2018 $-418.00K 0.00%
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
$2.04B -7,225.67%
US
$222.34M -875.49%
AU
$295.53M -1,130.77%
US
$-259.89M 806.47%
US
- -
US